Manjari Lahiri
496 posts
Manjari Lahiri
@SgRheumer
Rheumatologist, A/Prof @NUSMedicine 🇸🇬 @NUHSofficial || @AIIMS_NewDelhi ‘90-‘99 🇮🇳 || #RheumTwitter🦴|| #MedEd || Mummy of 2 || Dreamer || Views my own
Singapore Katılım Aralık 2010
142 Takip Edilen202 Takipçiler
Day1 #APLAR2025
Focus on #lupus 🦋
The new TRM-SLE tinyurl.com/TRMSLE elegantly elucidated by @EricFMorand focusing on indices that alter how patients #feel, #function or #survive
And @Lupusreference very energetic talk summarising current lupus trials
Exciting times 🤩
English
Manjari Lahiri retweetledi
@SirohiBhawna @BhatlaDr @aiims_newdelhi @dgafms_mod Congratulations to Dr. Bhatla from the AIIMS 1990 batch. We are proud to have been her students!
@Amitvermamds @SgRheumer @SleepnLetSleep @vibhusharmamd
English
4-year data from TREAT EARLIER @TheLancetRheum
⬇️ risk of seronegative RA for MTX arm (& 💉 IM triamcinolone)
How about just the IM 💉 steroid ?
Somehow not really convinced that treating with MTX makes sense?
What do you think? 🤔
#RheumTwitter
thelancet.com/journals/lanrh…
English
Shucks 😭 didn't make it!
Oh well, keep trying💪
😂
#ACR24
Mithu Maheswaranathan, MD@MithuRheum
Congrats to the influencers of #ACR24 & thanks for all your posts sharing knowledge from the conference!!! 🥳 @ACRheum @rheum_cat @RheumNow @MithuRheum @EBRheum @noellealicia242 @NamrataRheum @realcc @rheumarhyme #Rheumatology
English
So many options 🤩
But let's not forget that early diagnosis, close monitoring, improved adherence to treatment and minimising GC toxicity will probably have a larger impact in terms of absolute patient numbers and reach
#LupusNephritis
#Lupus
Laurent ARNAUD@Lupusreference
✅ Current pipeline of investigational agents / drug development in #Lupus, updated with #ACR2024 data ⬇️ What would you add? Which ones are the most promising? There is truly hope for patients with #SLE. Please do let me know if I have forgotten something & I will reupdate.
English
Not investing any time soon 😅 but this is a great summary!
Tae-young Kang@koreabioman
B-cell Depletion Race in AID 1 Identifying key players in this race could present an outstanding investment opportunity. Here’s how I approach this emerging field: $SANA $IPSC $FATE $CRBU $CRSP $ALLO $PSTX $ACET $TAK $NKTX $LEGN $NVS $BMY $AZN $AMGN $RHHBY $MRK $CGEM $IGMS $XNCR
English
Manjari Lahiri retweetledi
@petercgrayson @ACRheum PS not so rare in Asia and the Far East 🌏
English
@petercgrayson @ACRheum Ha ha yes I totally agree! It was a great session 💪🏽
English
Manjari Lahiri retweetledi
💡 New hope for severe/refractory #SLE: A-319 (CD3 x CD19 TCE) shows rapid and safe immune reset!
✅ Rapid B-cell depletion, autoantibody reduction, & organ improvement by W2
✅ No CRS or ICANS observed
📊 Could this be a game-changer in SLE therapy?
@Dr_AndreRibeiro
#ACR24
Washington, DC 🇺🇸 English
Manjari Lahiri retweetledi
#ACR24: The year of cell therapy in autoimmune diseases and redefining Tx paradigms!
🧬 Breakfree-1 CD19 CAR-T therapy shows sustained clinical remission in refractory #SLE and a safer profile.
🔬 Next-gen technology on the way. Stay tuned for more!
@Dr_AndreRibeiro
Washington, DC 🇺🇸 English
Manjari Lahiri retweetledi
Sarcoidosis is a granulomatous disorder that affects people of all racial and ethnic backgrounds. The pathogenesis of sarcoidosis remains incompletely understood. Learn more in the latest Interactive Medical Case: nej.md/3UQ4s6V
English
Clinical year in PREVIEW
Grace Wright @AWIRGROUP
#ACR24
3/3
💥Anti-obesity meds in RA/ AID
Observational databases (FORWARD - pan-US, community practices)
💪🏽 Improved PRO, APR
👉🏽But ONLY in obese pts
❓⬇️CV risk
New paradigm of combination Rx?
English
Clinical year in PREVIEW
Grace Wright @AWIRGROUP
#ACR24
2/3
💥Cell Rx in SLE
💡Autologous anti-CD19 B
💡NEX-T
💡CD3XCD19 TCE
Safety ✅ low CRS, no ICANS, deep depletion
👎🏽infections, neutropenia
English
Clinical year in PREVIEW
Grace Wright @AWIRGROUP
#ACR24
1/3
💥Biomarkers in SLE
Non-invasive urinary panel predicts BOTH active proliferative LN AND response ✅
💥GC sparing in SLE
Disruption of E3-X novel E3-ligase ⬆️GILZ
English
@asifdmcasif @debaditya_roy @LupusEurope @LADAOrg @LupusInitiative @Lupus_Chat @LupusCongress @LupusForum @LupusOrg @LUPUSUK @LupusResearch @Amansharmapgi @12VRavindran @DrVarshaBh88235 @JasmineNephro @PanktiMehta24 @LatikaGupta_ @ori_114 @DaniReumatologa @drkeithsiau @DrRadhikaBatra I would like to know too! I’d be worried to give full dose in combination with a CNI!
English
@debaditya_roy @LupusEurope @LADAOrg @LupusInitiative @Lupus_Chat @LupusCongress @LupusForum @LupusOrg @LUPUSUK @LupusResearch @Amansharmapgi @12VRavindran @DrVarshaBh88235 @JasmineNephro @PanktiMehta24 @SgRheumer @LatikaGupta_ @ori_114 @DaniReumatologa @drkeithsiau @DrRadhikaBatra Dose of MPAA? 1 gm/day or 2-3 gm/day?
English
🐺🦋 #Lupus #Guideline
🔥 Finally its here!
🌍 #Guideline on #LupusNephritis #2024
🌟Checkout the algorithm of how to approach #LN
🌟 Triple & Dual therapy defined
🌟 When to #Biopsy?
🌟 How to tackle Refractory LN?
& more..
✅️Check this out now!
#ACR24 #ACRambassador
English
Late breaking L19
Alexei Grom
#ACR24
Emapalumab: anti IFN y Ab, MAS in Still’s dz
💡Data pooled from 2 obs studies, n=49, mostly kids
✅ 1° outcome CR of ALL MAS criteria=53%, 69% if LDH excluded, 82% investigator determined remission, 95% survival
👎🏽TEAE = viral infections🦠
English
Manjari Lahiri retweetledi
✨ Breaking at #ACR24
KN5501 CAR-NK therapy is emerging as a safer and effective alternative to CAR-T for relapsed and refractory SLE patients.
✅ 50% DORIS remission
✅ 68.8% LLDAS (>6 months follow-up)
✅ No Grade ≥2 CRS or ICANS
@Dr_AndreRibeiro
Washington, DC 🇺🇸 English
Manjari Lahiri retweetledi
🔍 Why CAR-NK therapy works?
💥 Deep B-cell depletion + naïve B-cell reset.
💥 Complement normalization (C3, C4).
💥 Anti-dsDNA antibody reduction.
⚠️ Safety First! ⚠️
💡 No severe CRS
💡 No ICANS
💡 No major infections
@Dr_AndreRibeiro
Washington, DC 🇺🇸 English